Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Pfaller

Showing results (281-290 of 542) with videos related to

Pageof 55
Sort By:
Diagnostic Microbiology and Infectious Disease|April 1, 2000
Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin AmericaA C Gales, K A Gordon, W W Wilke, et al.
Journal of Clinical Microbiology|August 9, 2003
Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungiD J Diekema, S A Messer, R J Hollis, et al.
Antimicrobial Agents and Chemotherapy|February 27, 2003
In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolatesM A Pfaller, D J Diekema, S A Messer, et al.
Journal of Clinical Microbiology|November 1, 1994
Evaluation and characterization of multiresistant Enterococcus faecium from 12 U.S. medical centersH S Sader, M A Pfaller, F C Tenover, et al.
Journal of Chemotherapy (Florence, Italy)|February 21, 2007
Re-evaluation of the role of broad-spectrum cephalosporins against staphylococci by applying contemporary in-vitro results and pharmacokinetic-pharmacodynamic principlesH S Sader, S M Bhavnani, P G Ambrose, et al.
Antimicrobial Agents and Chemotherapy|April 1, 1991
Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolatesP C Fuchs, A L Barry, M A Pfaller, et al.
The Journal of Antimicrobial Chemotherapy|March 1, 1989
In-vitro susceptibility of nosocomial gram-negative bloodstream pathogens to quinolones and other antibiotics--a statistical approachM A Martin, M A Pfaller, P B Rojas, et al.
Diagnostic Microbiology and Infectious Disease|May 8, 1998
Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study GroupR N Jones, M A Pfaller, G V Doern, et al.
Journal of Chemotherapy (Florence, Italy)|April 1, 1991
Use of antimicrobial susceptibility testing for epidemiology and the selection of oral, parenteral and topical regimens for control of CAPD-associated Staphylococcus aureus infectionA Pignatari, R N Jones, M R Barrett, et al.
Journal of Clinical Microbiology|March 7, 2002
Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000M A Pfaller, D J Diekema, R N Jones, et al.
Pageof 55

Showing results (281-290 of 542) with videos related to

Sort By:
Pageof 55
Diagnostic Microbiology and Infectious Disease|April 1, 2000
Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin AmericaA C Gales, K A Gordon, W W Wilke, et al.
Journal of Clinical Microbiology|August 9, 2003
Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungiD J Diekema, S A Messer, R J Hollis, et al.
Antimicrobial Agents and Chemotherapy|February 27, 2003
In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolatesM A Pfaller, D J Diekema, S A Messer, et al.
Journal of Clinical Microbiology|November 1, 1994
Evaluation and characterization of multiresistant Enterococcus faecium from 12 U.S. medical centersH S Sader, M A Pfaller, F C Tenover, et al.
Journal of Chemotherapy (Florence, Italy)|February 21, 2007
Re-evaluation of the role of broad-spectrum cephalosporins against staphylococci by applying contemporary in-vitro results and pharmacokinetic-pharmacodynamic principlesH S Sader, S M Bhavnani, P G Ambrose, et al.
Antimicrobial Agents and Chemotherapy|April 1, 1991
Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolatesP C Fuchs, A L Barry, M A Pfaller, et al.
The Journal of Antimicrobial Chemotherapy|March 1, 1989
In-vitro susceptibility of nosocomial gram-negative bloodstream pathogens to quinolones and other antibiotics--a statistical approachM A Martin, M A Pfaller, P B Rojas, et al.
Diagnostic Microbiology and Infectious Disease|May 8, 1998
Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study GroupR N Jones, M A Pfaller, G V Doern, et al.
Journal of Chemotherapy (Florence, Italy)|April 1, 1991
Use of antimicrobial susceptibility testing for epidemiology and the selection of oral, parenteral and topical regimens for control of CAPD-associated Staphylococcus aureus infectionA Pignatari, R N Jones, M R Barrett, et al.
Journal of Clinical Microbiology|March 7, 2002
Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000M A Pfaller, D J Diekema, R N Jones, et al.
Pageof 55